Citations

Clear

133 citation(s) found for "SCHAID, D".

Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse Genome-Wide Association Study and Population-Specific Optimization
Smith, Johanna L. , Tcheandjieu, Catherine , Dikilitas, Ozan , Iyer, Kruthika , Miyazawa, Kazuo , Hilliard, Austin T. , Lynch, Julie A. , Rotter, Jerome I. , Chen, Yii‐Der Ida , Sheu, Wayne Huey‐Herng , Kanoni, Stavroula , Tsao, Philip S. , Ito, Kaoru , Kosel, Matthew , Schaid, Daniel J. , Chen, Yii-Der Ida , Hilliard, Austin , Lynch, Julie A , Chang, Kyong-Mi , Kanoni, Stavroula , Tsao, Philip S , Ito, Kaoru , Kosel, Matthew , Clarke, Shoa L , Schaid, Daniel J , Assimes, Themistocles L , Kullo, Iftikhar J , Dikilitas, Ozan , Rotter, Jerome I , Chang, Kyong‐Mi , Clarke, Shoa L. , Assimes, Themistocles L. , Kullo, Iftikhar J.

Mayo Clinic

Circulation: Genomic and Precision Medicine | February 21, 2024 | Volume: 17 | Issue: 3 | Pages: No page available

10.1161/circgen.123.004272 | PMID 38380516 Get It

BACKGROUND: Predictive performance of polygenic risk scores (PRS) varies across populations. To facilitate equitable clinical use, we developed PRS for coronary heart disease (CHD; PRS CHD ) for 5 genetic ancestry groups. METHODS: We derived ancestry-specific and multi-ancestry PRS CHD based on pruning and thresholding (PRS PT ) and ancestry-based continuous shrinkage priors (PRS CSx ) applied to summary statistics from the largest multi-ancestry genome-wide association study meta-analysis for CHD to date, including 1.1 million participants from 5 major genetic ancestry groups. Following training and optimization in the Million Veteran Program, we evaluated the best-performing PRS CHD in 176,988 individuals across 9 diverse cohorts. RESULTS: Multi-ancestry PRS PT and PRS CSx outperformed ancestry-specific PRS PT and PRS CSx across a range of tuning values. Two best-performing multi-ancestry PRS CHD (ie, PRS PTmult and PRS CSxmult ) and 1 ancestry-specific (PRS CSxEUR ) were taken forward for validation. PRS PTmult demonstrated the strongest association with CHD in individuals of South Asian ancestry and European ancestry (odds ratio per 1 SD [95% CI, 2.75 [2.41–3.14], 1.65 [1.59–1.72]), followed by East Asian ancestry (1.56 [1.50–1.61]), Hispanic/Latino ancestry (1.38 [1.24–1.54]), and African ancestry (1.16 [1.11–1.21]). PRS CSxmult showed the strongest associations in South Asian ancestry (2.67 [2.38–3.00]) and European ancestry (1.65 [1.59–1.71]), lower in East Asian ancestry (1.59 [1.54–1.64]), Hispanic/Latino ancestry (1.51 [1.35–1.69]), and the lowest in African ancestry (1.20 [1.15–1.26]). CONCLUSIONS: The use of summary statistics from a large multi-ancestry genome-wide meta-analysis improved the performance of PRS CHD in most ancestry groups compared with single-ancestry methods. Despite the use of one of the largest and most diverse sets of training and validation cohorts to date, improvement of predictive performance was limited in African ancestry. This highlights the need for larger genome-wide association study datasets of underrepresented populations to enhance the performance of PRS CHD .
Breast Cancer Polygenic-Risk Score Influence on Risk-Reducing Endocrine Therapy Use: Genetic Risk Estimate (GENRE) Trial 1-Year and 2-Year Follow-Up
Stan, Daniela , Kim, Julian O. , Schaid, Daniel J. , Carlson, Erin E. , Kim, Christina , Couch, Fergus J. , Vachon, Celine M. , Cooke, Andrew , Goldenberg, Benjamin A. , Pruthi, Sandhya , Couch, Fergus J. , Stan, Daniela L , Kim, Christina A , Sinnwell, Jason P , Vachon, Celine M. , Cooke, Andrew L , Goldenberg, Benjamin , Pruthi, Sandhya , Sinnwell, Jason P.

Mayo Clinic

Cancer Prevention Research | December 28, 2023 | Volume: 17 | Issue: 2 | Pages: 77-84

10.1158/1940-6207.capr-23-0256 | PMID 38154464 Get It

Abstract Refinement of breast cancer risk estimates with a polygenic-risk score (PRS) may improve uptake of risk-reducing endocrine therapy (ET). A previous clinical trial assessed the influence of adding a PRS to traditional risk estimates on ET use. We stratified participants according to PRS-refined breast cancer risk and evaluated ET use and ET-related quality of life (QOL) at 1-year (previously reported) and 2-year follow-ups. Of 151 participants, 58 (38.4%) initiated ET, and 22 (14.6%) discontinued ET by 2 years; 42 (27.8%) and 36 (23.8%) participants were using ET at 1- and 2-year follow-ups, respectively. At the 2-year follow-up, 39% of participants with a lifetime breast cancer risk of 40.1% to 100.0%, 18% with a 20.1% to 40.0% risk, and 16% with a 0.0% to 20.0% risk were taking ET (overall P = 0.01). Moreover, 40% of participants whose breast cancer risk increased by 10% or greater with addition of the PRS to a traditional breast cancer-risk model were taking ET versus 0% whose risk decreased by 10% or greater (P = 0.004). QOL was similar for participants taking or not taking ET at 1- and 2-year follow-ups, although most who discontinued ET did so because of adverse effects. However, these QOL results may have been skewed by the long interval between QOL surveys and lack of baseline QOL data. PRS-informed breast cancer prevention counseling has a lasting, but waning, effect over time. Additional follow-up studies are needed to address the effect of PRS on ET adherence, ET-related QOL, supplemental breast cancer screening, and other risk-reducing behaviors. Prevention Relevance: Risk-reducing medications for breast cancer are considerably underused. Informing women at risk with precise and individualized risk assessment tools may substantially affect the incidence of breast cancer. In our study, a risk assessment tool (IBIS-polygenic-risk score) yielded promising results, with 39% of women at highest risk starting preventive medication.
Age-Specific Incidence Rate For Dementia And Alzheimer’s Disease In NIA-LOAD/NCRAD and EFIGA Families (P2.148)
Faber, Kelley, Bird, Thomas D., Rosenberg, Roger N., Graff‐Radford, Neill R. , Farlow, Martin R. , Lantigua, Rafeal, Medrano, Martin , Schaid, Daniel J. , Mayeux, Richard , Vardarajan, Badri Narayan , Bennett, David A. , Boeve, Bradley F. , Goate, Alison , Sweet, Robert A. , Ottman, Ruth , Foroud, Tatiana

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.p2.148 Get It

Broadcasters, receivers, functional groups of metabolites and the link to heart failure progression using polygenic factors
Yazdani, Azam , Méndez-Giráldez, Raúl , Yazdani, Akram , Schaid, Daniel J. , Kong, Sek Won , Hadi, M. Wahdian Rijalil, Samiei, Ahmad, Clish, Clary B. , Kosorok, Michael R. , Elsea, Sarah H. , Schaid, Daniel, Won Kong, Sek , Clish, Clary , Mora, Samia , Elsea, Sarah , Hadi, Mohamad, Wittenbecher, Clemens , Lasky‐Su, Jessica , Marotta, Francesco , Mora, Samia , Muehlschlegel, Jochen D , Chasman, Daniel I. , Larson, Martin G.

Mayo Clinic

No container title available | August 18, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3246406/v1 | PMID 37645766 Get It

Abstract In a prospective study with records of heart failure (HF) incidence, we present metabolite profiling data from individuals without HF at baseline. We uncovered the interconnectivity of metabolites using data-driven and causal networks augmented with polygenic factors. Exploring the networks, we identified metabolite broadcasters, receivers, mediators, and subnetworks corresponding to functional classes of metabolites, and provided insights into the link between metabolomic architecture and regulation in health. We incorporated the network structure into the identification of metabolites associated with HF to control the effect of confounding metabolites. We identified metabolites associated with higher or lower risk of HF incidence, the associations that were not confounded by the other metabolites, such as glycine, ureidopropionic and glycocholic acids, and LPC 18:2. We revealed the underlying relationships of the findings. For example, asparagine directly influenced glycine, and both were inversely associated with HF. These two metabolites were influenced by polygenic factors and only essential amino acids which are not synthesized in the human body and come directly from the diet. Metabolites may play a critical role in linking genetic background and lifestyle factors to HF progression. Revealing the underlying connectivity of metabolites associated with HF strengthens the findings and facilitates a mechanistic understanding of HF progression.
Abstract 13386: The Association of High Polygenic Risk With Future Coronary Heart Disease Events Diminishes Later in Life
Smith, Johanna L. , Schaid, Daniel J. , Dikilitas, Ozan , Kullo, Iftikhar J.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.13386 Get It

Introduction: Polygenic risk scores (PRS) for coronary heart disease (CHD) are associated with incident CHD events. We assessed whether the strength of this association differs over the life course. Methods: We studied 7,958 genotyped participants of European-ancestry without CHD enrolled in the Atherosclerosis Risk in Communities Study (ARIC). Participants were 45-64 years old at the baseline visit occurring 1987-89 with follow up available through 2015. A genome-wide PRS for CHD composed of 1.7 million variants was computed for each participant. Incident CHD was defined as clinically adjudicated myocardial infarction including silent infarction, coronary revascularization, or fatal coronary event. An extended Cox model was constructed with age as the model time scale. The association of PRS with incident CHD was assumed to be log-linear and further modeled as a function of age assuming differing piecewise constant effect sizes across the intervals ≤55, 55-65, 65-80, and ≥80 years. The regression model also included the following covariates: sex, systolic blood pressure, total and HDL cholesterol, history of diabetes, antihypertensive medication use, and smoking status. Results: In the ARIC cohort (median enrollment age 54, interquartile range [IQR] 49-59, female 52%), over a median of 24.5 years (IQR 14.4-28.1), there were 1,872 incident CHD events. In comparison to average polygenic risk for CHD (50th percentile of PRS distribution), harboring high polygenic risk (95th percentile) was associated with a 2.9-fold increased risk of incident CHD (95% CI 2.12-3.95) up to age 55 years, independent of conventional risk factors. The strength of association was attenuated later in life (Hazard ratio, age 55-65, 2.5 [2.14-2.84]; age 65-80, 1.87 [1.68-2.07]; age ≥80, 1.78 [1.38-2.31]) Conclusions: A genome-wide PRS for CHD is more strongly associated with incident coronary events at younger age. The strength of association declined later in life while remaining significant. The age-dependent association of PRS with CHD may need to be accounted for in risk prediction models.
Abstract 10360: Polygenic Risk Score, Rare Monogenic Variants, and Family History Have Independent and Additive Effects on the Risk of Coronary Heart Disease
Hamed, Marwan , Miller, Alexandra , Bangash, Hana , Nigbur, Scott, Kamzabek, Arailym, Norland, Kristján , Kosel, Matt, Schaid, Daniel J. , Saadatagah, Seyedmohammad , Nigbur, Scott, Kamzabek, Arailym, Kosel, Matthew , Kullo, Iftikhar J.

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.10360 Get It

Introduction. We assessed the effects of a polygenic risk score (PRS), monogenic variants (Mono + ), and family history (FamHx) on the risk of coronary heart disease (CHD) and whether incorporating a PRS into the Pooled Cohort Equations (PCE) improves risk prediction. Method. In 199,997 UK Biobank participants, we calculated a PRS CHD (metaGRS, based on ~1.6 million single nucleotide variants), identified individuals with monogenic etiology (presence of a pathogenic variant in LDLR , APOB , or PCSK9 ), and ascertained family history of CHD (CHD in a first-degree relative). Odds of CHD (myocardial infarction/ coronary revascularization/ cardiovascular death) associated with PRS CHD , Mono + , and FamHx at age 55 were computed using logistic regression analyses adjusted for age, sex, and first 4 principal components of ancestry. We combined PRS CHD and PCE into an integrated score (IS) and assessed net reclassification using an actionable risk threshold of 7.5%. Results. The odds ratio (OR) for CHD in the top 5 th percentile of PRS CHD (PRS P95 ), Mono + , and FamHx were 3.37 (2.98 - 3.81), 2.68 (1.67 - 4.07), and 1.61 (1.47 - 1.76), respectively (all p<0.001). These effects were independent and similar in different subgroups. ( Figure 1-A ) Compared to PRS Q2-4 Mono - (3 middle quintiles of PRS CHD and no monogenic variants), the OR for CHD ranged from 1.73 (0.28 - 5.48, p = 0.446) in PRS Q1 Mono + to 5.10 (2.14 - 10.24, p <0.001) in PRS Q5 Mono + . A similar pattern was seen for other combinations, indicating additive effects ( Figure 1-B ). Incorporating PRS CHD into PCE resulted in a net reclassification improvement of 4.56%. Compared to those with high PCE and low IS, the hazard ratio for CHD in those with low PCE and high IS was 1.48 (1.34 - 1.64, p <0.001). Conclusion. The CHD risk associated with PRS CHD , monogenic variants, and family history is independent and additive. Combining PRS CHD and PCE improved risk prediction, that could improve further by adding monogenic variants and family history.
Quantifying factors that affect polygenic risk score performance across diverse ancestries and age groups for body mass index
Hui, Daniel J. , Xiao, Brenda , Irvin, Marguerite R. , Kullo, Iftikhar, Limdi, Nita A. , Liu, Cong , Namjou, Bahram , Puckelwartz, Megan J. , Schaid, Daniel J. , Tiwari, Hemant K., Wei, Wei‐Qi, Ritchie, Marylyn D. , Liu, Cong , Puckelwartz, Megan J , Dikilitas, Ozan , Freimuth, Robert R. , Jarvik, Gail P. , Kottyan, Leah C. , Luo, Yuan , Verma, Shefali S. , Kim, Dokyoon

Mayo Clinic

Biocomputing 2023 | November 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: 437-448

10.1142/9789811270611_0040 Get It

Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer
Fasching, Peter A. , Liu, Duan , Scully, Steve, Ingle, James N. , Lyra, Paulo C. , Rack, Brigitte , Hein, Alexander , Ekici, Arif B. , Reis, André , Schneeweiß, Andreas , Tesch, Hans , Heinrich, Georg, Beckmann, Matthias W. , Ruebner, Matthias , Huebner, Hanna , Lambrechts, Diether , Madden, Ebony , Shen, Jess, Romm, Jane, Doheny, Kim, Jenkins, Gregory D. , Cunningham, Julie M. , Janni, Wolfgang , Schaid, Daniel J. , Häberle, Lothar , Weinshilboum, Richard M. , Wang, Liewei , Lambrechts, Diether , Lambrechts, Diether , Li, Liang , Fridley, Brooke L , Cunningham, Julie M , Janni, Wolfgang , Monteiro, Alvaro N , Ingle, J , Lambrechts, Diether , Hein, Alexander , Ekici, Arif B , Reis, André , Morais Lyra, Paulo Cilas , Liu, Duan , Fehm, Tanja , Carlson, Erin E. , Li, Liang , Fridley, Brooke L. , Monteiro, Álvaro N.A. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Cancer Research | June 27, 2022 | Volume: 28 | Issue: 15 | Pages: 3342-3355

10.1158/1078-0432.ccr-20-4774 | PMID 35653140 Get It

Abstract Purpose: To identify molecular predictors of grade 3/4 neutropenic or leukopenic events (NLE) after chemotherapy using a genome-wide association study (GWAS). Experimental Design: A GWAS was performed on patients in the phase III chemotherapy study SUCCESS-A (n = 3,322). Genotyping was done using the Illumina HumanOmniExpress-12v1 array. Findings were functionally validated with cell culture models and the genotypes and gene expression of possible causative genes were correlated with clinical treatment response and prognostic outcomes. Results: One locus on chromosome 16 (rs4784750; NLRC5; P = 1.56E-8) and another locus on chromosome 13 (rs16972207; TNFSF13B; P = 3.42E-8) were identified at a genome-wide significance level. Functional validation revealed that expression of these two genes is altered by genotype-dependent and chemotherapy-dependent activity of two transcription factors. Genotypes also showed an association with disease-free survival in patients with an NLE. Conclusions: Two loci in NLRC5 and TNFSF13B are associated with NLEs. The involvement of the MHC I regulator NLRC5 implies the possible involvement of immuno-oncological pathways.
Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study
Glazer, Andrew M. , Davogustto, Giovanni , Shaffer, Christian M., Desai, Reshma R. , Farber‐Eger, Eric , Dikilitas, Ozan , Shang, Ning , Muhammad, Ayesha , Shaffer, Lauren Lee, Kalash, Olivia R., Bland, Harris T. , Yoneda, Zachary T. , Mitchell, Devyn , Kroncke, Brett M. , Jarvik, Gail P. , Gordon, Allan , Larson, Eric B. , Manolio, Teri A. , Luo, Jonathan Z. , Schaid, Daniel J. , Namjou, Bahram , Singhal, Ashutosh , Liu, Cong , Ralston, James D. , Leppig, Kathleen A. , Håkonarson, Håkon , Sleiman, Patrick , Sohn, Sunghwan , Network, the eMERGE, Denny, Joshua C. , Wei, Wei‐Qi, Shoemaker, M. Benjamin , Roden, Dan M. , Ralston, James D. , Farber-Eger, Eric H , Dikilitas, Ozan , Mosley, Jonathan D , Van Driest, Sara L , Wells, Quinn S , Wada, Yuko , Yoneda, Zachary T , Kroncke, Brett M , Kullo, Iftikhar J , Jarvik, Gail P , Gordon, Adam S , Manolio, Teri A , Mirshahi, Tooraj , Schaid, Daniel, Alsaied, Tarek , Hripcsak, George , McNally, Elizabeth M , Sohn, Sunghwan , Glessner, Joseph , Wei, Wei-Qi , George, Alfred L , Shoemaker, M Benjamin , Roden, Dan M. , Hakonarson, Hakon , Denny, Joshua C , Bland, Sarah T , Liu, Cong , Glazer, Andrew M , Vanoye, Carlos G. , Pacheco, Jennifer A. , Yang, Tao , Driest, Sara L. Van , Wells, Quinn S. , Wada, Yuko , Kullo, Iftikhar J. , Singh, Rajbir , Weng, Chunhua , McNally, Elizabeth M. , Chung, Wendy K. , Carrell, David , Network, the eMERGE, George, Alfred L.

Mayo Clinic

Circulation | December 21, 2021 | Volume: 145 | Issue: 12 | Pages: 877-891

10.1161/circulationaha.121.055562 | PMID 34930020 Get It

Background: Sequencing Mendelian arrhythmia genes in individuals without an indication for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) variants. However, the extent to which these variants are associated with clinically meaningful phenotypes before or after return of variant results is unclear. In addition, the majority of discovered variants are currently classified as variants of uncertain significance, limiting clinical actionability. Methods: The eMERGE-III study (Electronic Medical Records and Genomics Phase III) is a multicenter prospective cohort that included 21 846 participants without previous indication for cardiac genetic testing. Participants were sequenced for 109 Mendelian disease genes, including 10 linked to arrhythmia syndromes. Variant carriers were assessed with electronic health record–derived phenotypes and follow-up clinical examination. Selected variants of uncertain significance (n=50) were characterized in vitro with automated electrophysiology experiments in HEK293 cells. Results: As previously reported, 3.0% of participants had P/LP variants in the 109 genes. Herein, we report 120 participants (0.6%) with P/LP arrhythmia variants. Compared with noncarriers, arrhythmia P/LP carriers had a significantly higher burden of arrhythmia phenotypes in their electronic health records. Fifty-four participants had variant results returned. Nineteen of these 54 participants had inherited arrhythmia syndrome diagnoses (primarily long-QT syndrome), and 12 of these 19 diagnoses were made only after variant results were returned (0.05%). After in vitro functional evaluation of 50 variants of uncertain significance, we reclassified 11 variants: 3 to likely benign and 8 to P/LP. Conclusions: Genome sequencing in a large population without indication for arrhythmia genetic testing identified phenotype-positive carriers of variants in congenital arrhythmia syndrome disease genes. As the genomes of large numbers of people are sequenced, the disease risk from rare variants in arrhythmia genes can be assessed by integrating genomic screening, electronic health record phenotypes, and in vitro functional studies. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier; NCT03394859.
Penalized mediation models for multivariate data
Schaid, Daniel J. , Dikilitas, Ozan , Kullo, Iftikhar J. , Sinnwell, Jason P , Kullo, Iftikhar J , Dikilitas, Ozan , Sinnwell, Jason P.

Mayo Clinic

Genetic Epidemiology | October 21, 2021 | Volume: 46 | Issue: 1 | Pages: 32-50

10.1002/gepi.22433 | PMID 34664742 Get It

AbstractStatistical methods to integrate multiple layers of data, from exposures to intermediate traits to outcome variables, are needed to guide interpretation of complex data sets for which variables are likely contributing in a causal pathway from exposure to outcome. Statistical mediation analysis based on structural equation models provide a general modeling framework, yet they can be difficult to apply to high‐dimensional data and they are not automated to select the best fitting model. To overcome these limitations, we developed novel algorithms and software to simultaneously evaluate multiple exposure variables, multiple intermediate traits, and multiple outcome variables. Our penalized mediation models are computationally efficient and simulations demonstrate that they produce reliable results for large data sets. Application of our methods to a study of vascular disease demonstrates their utility to identify novel direct effects of single‐nucleotide polymorphisms (SNPs) on coronary heart disease and peripheral artery disease, while disentangling the effects of SNPs on the intermediate risk factors including lipids, cigarette smoking, systolic blood pressure, and type 2 diabetes.